EGRP News Flash - August 26, 2008

RFA for Epigenomics of Human Health and Disease – Applications Due October 28, 2008

On behalf of the National Institutes of Health (NIH) Roadmap Epigenomics Program (, the National Cancer Institute's (NCI) Epidemiology and Genetics Research Program (EGRP) announces a funding opportunity announcement (FOA) that invites applications that propose research to transform our knowledge of how the epigenome defines and contributes to human disease.

This FOA requires applicants to propose projects that employ unbiased, global approaches in human cells (or with rare exceptions, cells from mammalian models) to correlate alterations in epigenomic structure/marks with disease, aging, or environmental perturbation. Following the initial global mapping, applicants may also propose to conduct epigenetic analyses to reveal the function or significance of target gene regions or loci identified during the initial global screen. Because the primary focus of an application should be the application of global mapping approaches across the genome, any proposed epigenetic analyses should be considered as follow up and secondary to the initial global mapping.

Examples of disease-related research areas that address physiologically compromised, abnormal or diseased states include:

  • perturbation due to exogenous exposure to dietary, chemical, social, or behavioral factors that may contribute to human disease
  • abnormal regulation of fundamental processes during critical stages of life (e.g. development, reproduction, aging) resulting in human disease
  • dysregulation of fundamental biological processes (e.g. inflammation, apoptosis, oxidative stress) that underlie multiple diseases.

Applicants should propose studies involving human cells and tissues (except under special circumstances) and provide a rationale for the selection of cells/tissues for establishing the epigenomic maps. The rationale should describe how understanding changes in epigenomic marks or features, and their possible interactions, in perturbed or diseased states as compared to normal or healthy states will disrupt current paradigms concerning disease etiology or progression or how it will create new paradigms where none exists.

This FOA will utilize the R01 grant mechanism. These R01s may propose a maximum of five years of support. Awards issued under this FOA are contingent upon the availability of funds and the submission of a sufficient number of meritorious applications. The anticipated number of awards is 12-16. A total of $8 million in FY 2009 has been committed to support this FOA.

A registration process is necessary before submission and applicants are highly encouraged to start the process at least four (4) weeks prior to the grant submission date. The opening date for this announcement is September 28, 2008. On-time submission requires that applications be successfully submitted to no later than 5:00 p.m. local time (of the applicant institution/organization) on October 28, 2008.

For general questions about cancer epigenomics, contact EGRP's Mukesh Verma, Ph.D., Chief, Methods and Technologies Branch, and Acting Chief, Host Susceptibility Factors Branch.

  • Access the NIH Guide for Grants and Contracts for details: RFA-RM-08-017External Web Site Policy (R01)

Return to Top